DB:2MJ

Stock Analysis Report

Executive Summary

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States.


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has Aevi Genomic Medicine's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2MJ's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-9.3%

2MJ

0.4%

DE Biotechs

0.2%

DE Market


1 Year Return

-16.9%

2MJ

9.0%

DE Biotechs

14.4%

DE Market

Return vs Industry: 2MJ underperformed the German Biotechs industry which returned 8.8% over the past year.

Return vs Market: 2MJ underperformed the German Market which returned 10.7% over the past year.


Shareholder returns

2MJIndustryMarket
7 Day-9.3%0.4%0.2%
30 Day-14.5%-2.1%0.9%
90 Day16.7%8.0%4.6%
1 Year-16.9%-16.9%9.2%9.0%17.9%14.4%
3 Year-96.8%-96.8%45.5%43.9%15.7%5.6%
5 Yearn/a12.8%10.5%23.4%6.5%

Price Volatility Vs. Market

How volatile is Aevi Genomic Medicine's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aevi Genomic Medicine undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Aevi Genomic Medicine is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Aevi Genomic Medicine has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of 2MJ’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Aevi Genomic Medicine regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Aevi Genomic Medicine forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

34.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aevi Genomic Medicine has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Aevi Genomic Medicine performed over the past 5 years?

0.05%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2MJ is currently unprofitable.

Growing Profit Margin: 2MJ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2MJ is unprofitable, but has reduced losses over the past 5 years at a rate of 0.05% per year.

Accelerating Growth: Unable to compare 2MJ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2MJ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 2MJ's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Aevi Genomic Medicine's financial position?


Financial Position Analysis

Short Term Liabilities: 2MJ has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 2MJ has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 2MJ is debt free.

Reducing Debt: 2MJ's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 2MJ has a low level of unsold assets or inventory.

Debt Coverage by Assets: 2MJ has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2MJ has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 2MJ has less than a year of cash runway if free cash flow continues to reduce at historical rates of -11.5% each year


Next Steps

Dividend

What is Aevi Genomic Medicine's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2MJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2MJ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2MJ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2MJ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2MJ's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Mike Cola (59yo)

6.4yrs

Tenure

US$1,331,623

Compensation

Mr. Michael F. Cola, also known as Mike, has been the Chief Executive Officer, President and Director of Aevi Genomic Medicine, Inc. since September 13, 2013. Mr. Cola is an Independent Director of Phathom ...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD1.33M) is above average for companies of similar size in the German market ($USD425.50K).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Cola
CEO, President & Director6.4yrsUS$1.33m2.92% $379.4k
Garry Neil
Chief Scientific Officer5.6yrsUS$865.96k2.78% $362.1k
Michael McInaw
CFO & Controller0.7yrsno data0.021% $2.7k

5.6yrs

Average Tenure

59yo

Average Age

Experienced Management: 2MJ's management team is seasoned and experienced (5.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Cola
CEO, President & Director6.4yrsUS$1.33m2.92% $379.4k
Sol Barer
Non-Executive Chairman7.6yrsUS$71.80kno data
Eugene Bauer
Independent Director18.9yrsUS$58.40k0.21% $27.7k
Joseph Grano
Independent Director6.9yrsUS$65.53k0.21% $26.7k
Barbara Duncan
Independent Director4.6yrsUS$80.90k0.077% $10.0k
Alastair John Clemow
Independent Director9.5yrsUS$70.40k0.074% $9.6k
Hákon Hákonarson
Member of Advisory Board0yrsno datano data
Stephen Spielberg
Member of Scientific Advisory Board4.3yrsno datano data
Matthew Bayley
Director2.2yrsUS$60.90kno data

6.7yrs

Average Tenure

63yo

Average Age

Experienced Board: 2MJ's board of directors are considered experienced (6.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 2MJ insiders have bought and sold the same number of shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.7%.


Top Shareholders

Company Information

Aevi Genomic Medicine, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aevi Genomic Medicine, Inc.
  • Ticker: 2MJ
  • Exchange: DB
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$14.377m
  • Listing Market Cap: US$13.001m
  • Shares outstanding: 77.71m
  • Website: https://www.aevigenomics.com

Number of Employees


Location

  • Aevi Genomic Medicine, Inc.
  • 435 Devon Park Drive
  • Suite 715
  • Wayne
  • Pennsylvania
  • 19087
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNMXNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJan 2009
2MJDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2009

Biography

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidate is AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn’s disease. The company also develops AEVI-005, a monoclonal antibody, which is in preclinical research program for the treatment of auto-immune pediatric disease. In addition, it focuses on evaluating the anti-seizure activity of AEVI-004 in a preclinical model as part of the National Institutes of Health Epilepsy Treatment Screening Program. It has a development and option agreement with Kyowa Hakko Kirin Co., Ltd. related to AEVI-002 and AEVI-005. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/03 22:45
End of Day Share Price2020/02/03 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.